Jagsonpal Pharmaceuticals Ltd
Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India)
Ph.: +91 124 4406710; E-mail: info@jagsonpal.com; Website: www.jagsonpal.com
CIN. : L74899DL1978PLC009181

My Sakhi
A CSR Initiative

July 29, 2026

The Department of Corporate Services- Listing **BSE Ltd,** Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 **Scrip Code: 507789**	The Department of Corporate Services- Listing **National Stock Exchange of India Ltd** Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 **Symbol: JAGSNPHARM**

Subject: Press Release for Unaudited Financial Results for quarter ended June 30, 2026

Dear Sir/ Madam,

In terms of regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations,2015, please find enclosed herewith a copy of Press Release along with Investor's presentation for the Unaudited Financial results for the quarter ended June 30, 2026.

We request you to take the above on record.

Thanking you,

For **Jagsonpal Pharmaceuticals Limited**

PRATHAM RAWAL
Digitally signed by PRATHAM RAWAL
Date: 2026.07.29 18:04:27 +05'30'

Pratham Rawal

Company Secretary & Compliance officer

Jagsonpal Pharmaceuticals Ltd announces Q1 FY27 Results

Strong Start to FY27

Revenue up 9%, PAT up 22% and cash reserves at ₹1,700 Mn;

Aequitas – Strong platform for foray into hospital business

Gurugram, July 29, 2026: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) today announced the audited financial results for the quarter and year ended June 30, 2026.

₹ in Mn	Q1FY27	Q4FY26	QoQ %	Q1FY26	YoY%
Revenue	822	642	28.1%	756	8.8%
Operating EBITDA*	191	106	80.7%	157	21.4%
EBITDA Margin*	23.2%	16.4%	675 bps	20.8%	241 bps
PAT	132	88	50.5%	108	22.2%

**Operating EBITDA and EBITDA margins before ESOP*

Q1FY27 Key Highlights:

- **Growing quarter across all Metrics:** Revenue +9% YoY | Op. EBITDA +21% YoY | PBT +23% YOY | PAT +22% YoY, reflecting strong operating momentum

- **EBITDA indicating sustainable growth:** Op. EBITDA rose to ₹191 Mn, driving margin expansion to 23.2% (+241 bps YoY), driven by operating leverage through improved MR productivity

- **Another quarter of higher profitability:** PAT reached ₹132 Mn with margins expanding to 16.0%,

- **Growth delivered without compromising liquidity:** Cash balance remained robust at ₹1,700 Mn despite a ₹400 Mn buyback, highlighting the strength of business model and disciplined execution

- **Capital deployed, financial strength retained:** Completed Aequitas acquisition from internal accruals and yet maintaining a debt-light, cash-rich balance sheet

- **Value creation underway**: Starting with Aequitas's revenue base of ₹533 Mn, driving higher revenue and improved profitability from H2FY27; targeting of ₹100+ Mn EBITDA by Year 2 post-integration.

Commenting on the performance for the quarter, Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals Limited said,

"Q1FY27 reflects sustained traction in our business, with revenue growing 9% YoY, driven by higher MR productivity and continued strength across our key brands. We significantly outperformed the industry, with Pharmarack reporting 18.9% growth for Jagsonpal versus 11.6% for the IPM, leading to a 4 ranks improvement to #88 in the Indian pharmaceutical market.

This translated into strong financial performance, with Op. EBITDA rising 21% YoY to ₹19 crore, Op. EBITDA margin expanding 241 bps to 23.2%, and PAT growing 22%.

We recently completed the acquisition of a controlling stake (85%) in Aequitas Healthcare, marking our entry into the hospital supplies segment. We also concluded our ₹40 crore share buyback resulting in an ROCE improvement by 340 bps. Even with these capital allocation initiatives, we ended the quarter with a healthy cash balance of ₹170 crore.

With a stronger business franchise, disciplined capital allocation, and multiple growth levers in place, we remain confident of sustaining profitable growth while pursuing value-accretive inorganic opportunities."

ABOUT JAGSONPAL PHARMACEUTICALS LIMITED

Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over four decades in the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, Dermatology and Child-care segments. Over the years, the Company has successfully built multiple brands that today hold market-leading positions in their respective segments. It has created a strong niche for itself with 20+ brands amongst Top 5 brands in the molecule category, extensive pan-India presence and an experienced sales team of ~1,000 professional sales representatives.

The company is listed on the National Stock Exchange Limited (JAGSNPHARM) and Bombay Stock Exchange (Scrip code: 507789) and is headquartered in Delhi.

For more information, please visit: www.jagsonpal.com

Company contact	Investor Relations Team
Email: cs@jagsonpal.com, Tel: +91 124 4406710 Jagsonpal Pharmaceuticals Limited CIN: L74899DL1978PLC009181 Registered Office: Innov8 3rd Floor, Plot No. 211, Okhla Phase-3, , New Delhi, Delhi, 110020 Corporate Office: Nimai Tower, 3rd floor, Udyog Vihar, Gurugram, Haryana – 122015	Soumya Chhajed Email- soumya@goindiaadvisors.com Mobile: +91-8619707750

Jagsonpal Pharmaceuticals Limited

Q1FY27 Investor Presentation

29th July 2026

Safe Harbor

This presentation contains statements that constitute "forward looking statements" including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and several risks, uncertainties and other important factors that could cause actual developments and results to differ materially from our expectations.

These factors include, but not limited to: 1) change in the general market and macro-economic conditions, 2) governmental and regulatory trends, 3) successful implementation of our strategy, R&D efforts, growth & expansion plans and technological changes, 4) movements in currency exchange and interest rates, 5) increase in the competitive pressures and technological developments, 6) changes in the financial conditions of third parties dealing with us, 7) changes in laws and regulations that apply to our customers, suppliers and the pharmaceutical industry.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Jagsonpal Pharmaceuticals Limited may vary materially from those described in the relevant forward-looking statements.

The information contained in this presentation is current, and if not stated otherwise, made as of the date of this presentation. The Company undertakes no obligation to update or revise any information in this presentation because of new information, future events or otherwise.

This presentation is for information purpose only and is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, or the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India.

Management Commentary

"Q1FY27 reflects sustained traction in our business, with revenue growing 9% YoY, driven by higher MR productivity and growth across key brands. We significantly outperformed the industry, with Pharmarack reporting 18.9% growth for Jagsonpal versus 11.6% for the IPM, leading to a 4 ranks improvement to #88 in the Indian pharmaceutical market.

This translated into strong financial performance, with Op. EBITDA rising 21% YoY to ₹19 crore, Op. EBITDA margin expanding 241 bps to 23.2%, and PAT growing 22%.

We recently completed the acquisition of a controlling stake (85%) in Aequitas Healthcare, marking our entry into the hospital supplies business. We also concluded our ₹40 crore share buyback resulting in ROCE improvement by 340 bps. Even with these capital allocation initiatives, we ended the quarter with a healthy cash balance of ₹170 crore.

With a stronger business franchise, disciplined capital allocation, and multiple growth levers in place, we remain confident of sustaining profitable growth while pursuing value-accretive inorganic opportunities."

Manish Gupta
Managing Director

High Governance Standards

Innovation Backed Portfolio Expansion

Financial Strength fuels Strategic Agility

Q1 FY27 Highlights

Strong Financial Delivery In Q1 FY27

Q1FY27 Rev up 9% | Op. EBITDA up 21% | PAT up 22% | Cash balance at ₹ 1,700 Mn

Consistent revenue trajectory

Q1 revenue stood at ₹ 822 Mn and delivered a 9% YoY growth.

EBITDA Expands ahead of revenue

Op. EBITDA of ₹ 191 Mn, an uptick of 21.4% YoY; Margin at 23.2%, 241 bps expansion; demonstrating strong operating leverage.

PAT growth reflects strong execution

Net Profit rose to ₹ 132 Mn with margins expanding by 176 bps YoY to 16.0% with a growth of 22.2% YoY underscoring sustained profitability momentum.

Strong cash position enables future growth

Healthy cash balance at ₹ 1,700 Mn, 50% recoup of buyback payout, underscoring strong business quality and hygiene. Supports inorganic initiatives.

Financial Highlights: Q1 FY27

(All values in ₹ Mn)



* EBITDA and EBITDA margin is calculated Pre-ESOP

Income Statement

(All values in ₹ Mn)

Particulars	Q1 FY27	Q4 FY26	% Change	Q1 FY26	% Change
Revenue from Operations	**822**	**642**	**28.1%**	**756**	**8.8%**
Total Expenses	(632)	(537)	17.7%	(599)	5.4%
EBITDA*	**191**	**106**	**80.7%**	**157**	**21.4%**
EBITDA Margin*	**23.2%**	**16.4%**	**41.1%**	**20.8%**	**11.6%**
Other Income	28	32	-10.6%	28	0.3%
ESOP Cost	(18)	6	-	(15)	22.0%
Depreciation	(21)	(23)	-7.6%	(24)	-9.0%
EBIT	**179**	**120**	**49.3%**	**147**	**22.1%**
EBIT Margin	**21.8%**	**18.7%**	**16.6%**	**19.4%**	**12.3%**
Finance Cost	(3)	(3)	-0.4%	(3)	-1.2%
PBT	**177**	**118**	**50.4%**	**144**	**22.5%**
PBT Margin	**21.5%**	**18.3%**	**17.4%**	**19.1%**	**12.7%**
Tax	(45)	(30)	50.0%	(36)	23.5%
PAT	**132**	**88**	**50.5%**	**108**	**22.2%**
PAT %	**16.0%**	**13.6%**	**17.5%**	**14.3%**	**12.3%**

- EBITDA and EBITDA margin is calculated Pre-ESOP

Key Balance Sheet Items

(All values in ₹ Mn)

Particulars	30-Jun-26	31-Mar-26	30-Jun-25
Shareholders Funds*	2,548*	2,762	2,535
Tangible Assets	6	6	6
Intangibles	763	780	837
Right of Use Assets	64	68	80
Financial Assets (Cash & Equivalents)	1,700	1,907	1,609
Other Non-Current Assets (Net)	28	26	48
Lease liabilities	78	82	91
Net Working Capital	120	110	99

* Reduction on account of Buy-back of shares

Power Brand Building : Niche Dominators Driving Growth

JAGSONPAL

Top 10 brands constitutes ~ 58% of revenue, with 9 of them ranked in top #5

		Brand MAT			Molecule MAT		
Rank	Brand	Jun'26	Jun'25	Gr%	Jun'26	Jun'25	Gr%
1	Indocap	41	39	4%	54	52	4%
2	Maintane Inj.	34	24	43%	166	135	23%
2	Metadec	26	24	5%	144	153	-5%
1	Lycored	21	18	16%	98	90	8%
2	Equirex	13	13	2%	121	113	8%
21	Divatrone	12	10	11%	1,253	1,159	8%
1	Maintane Tab	13	9	55%	24	20	19%
3	Endoreg	10	8	24%	92	98	-7%
4	Doxypal DR-L	8	9	-4%	248	245	1%
4	PRU	7	6	23%	292	275	6%

Source : Pharmarack

Consistent delivery of Operational Excellence

FY22-26: PAT 2.4x; Cash balance 2.5x; FCF 8x

Revenue (Rs Mn)



Gross Profit (Rs Mn)*



Op. EBITDA (Rs Mn)*



Operational PAT (Rs Mn)



Cash position (Rs Mn)



FCF* (Rs Mn)



Excellence across Key Performance Parameters

Working capital reduced 69%; Dividend payout increased 2.5x; PAT margins expanded 700 bps while FCF conversion reached 92%

CAPITAL EFFICIENCY
Capital Optimized for Growth

SHAREHOLDER RETURNS
Rewarding shareholders, enhancing payouts

CASH GENERATION
Strong margins; Stronger FCF

NWC (Days)



ROCE % and ROE %



FCF Conversion (FCF */EBITDA)



NWC (₹ Mn) and % of Sales



Dividend Payout



Strong focus on consistent and enhanced shareholder returns

Margin Expansion (%)



* FCF = CFO +/- Changes in WC - Capex - Lease Rentals
** FY26 Dividend includes onetime special dividend @ 75%

Aequitas Healthcare Acquisition

Accelerating Jagsonpal into a Leading Specialty Pharma Company

A strategically transformative acquisition that expands our specialty portfolio, enhances hospital access, improves scale and accelerates our long-term growth trajectory.

KEY INVESTMENT HIGHLIGHTS

SPECIALTY PORTFOLIO

HOSPITAL ACCESS

SCALE

GROWTH ACCELERATION

85%	15%	₹20.8 Cr	₹53.3 Cr	NIL
STAKE ACQUIRED and it is now a Subsidiary	ENSURING CONTINUITY of existing promoters	ALL-CASH Consideration	FY26 REVENUE	Debt

About Aequitas

₹PAN India Hospital Platform with 1,000+ Relationships

JAGSONPAL

COMPANY SNAPSHOT

7 YEARS OLD

Established specialty-focused pharmaceutical company

Headquartered in Mumbai

HOSPITAL + Gx

PAN INDIA PRESENCE

Strong coverage across geographies

BUSINESS FOOTPRINT

1,000+ HOSPITALS

Strong presence across pan-India hospital chains

4,000+ DOCTORS

Deep relationships with specialists & key prescribers

49 Hospital sales Executives

Experienced field force driving institutional reach

Top Customers

- Medanta
- Max Hospital
- Manipal Hospital
- Cloudnine Hospital
- Rainbow Hospital
- & Many More

FINANCIAL SNAPSHOT (₹ Cr)

PARTICULARS	FY24	FY25	FY26
NET REVENUE	53.7	56.2	53.3
GROSS PROFIT	10.4	12.2	12.0
EBITDA	0.7	0.7	0.5
PAT	0.2	0.1	0.1

The Value Creation Roadmap

Creating a ₹10 Cr EBITDA Opportunity Through Scale, Synergies & Integration

JAGSONPAL

EXPANDED BUSINESS REACH (FY27E)

	JPL	Aequitas	Combined
Hospitals	0	1,000+	1,000+
Doctors	~50,000+	4,000+	~54,000+
Field Force (MRs)	~950+	49	~1,000+

SYNERGY ROADMAP → VALUE CREATION

REVENUE SYNERGIES

- Cross-sell JPL portfolio across 1,000+ hospitals
- Entry into institutional hospital tenders
- First prescription generation opportunity
- Leverage 4,000+ Drs for deeper reach

+

COST SYNERGIES

- Elimination of duplicate overheads
- Consolidation of supply chain
- Generics rationalisation for better efficiency
- Stronger operating leverage & margin improvement

OUTLOOK & FINANCIAL IMPACT

Current Revenue (FY26)

₹53 Cr

>

Targeting

~₹10 Cr EBITDA

by Year 2

>

Higher contribution and profitability from FY28 onwards

Integration Progress

Key Initiatives & Strategic Benefits

KEY INITIATIVES

Ventrixa Launched

- Aztreonam + Avibactam combination launched.
- Growing segment at ₹20.7 Cr, targeting
- ₹1,452 Cr Meropenem market (+12.9% YoY)

Cross-sell Opportunity

- Cross-sell of JPL brands to be initiated

Supply Chain

- Areas of integration identified & initiated

Finance

- Governance structure aligned with JPL

STRATEGIC BENEFITS

Immediate Hospital Channel Access

- Ready access to the hospital channel & institutional Drs network which would take ~4-6 years to build organically
- Potential for core JPL brands to enter Hospital formulary in 1-2 years
- Bulk institutional sales — large and predictable volumes within the period of tender

Accelerated Key Prescriber Relationships

- Hospital KOL coverage will start for JPL
- Sticky business with potential revenue spill-over into retail as well

First Prescription Generation Opportunity

- All top Drs now associated with Hospitals; first prescription generated at Hospitals
- JPL's portfolio to be added through Aequitas's hospital channel
- Excellent platform for pipeline products like Upadacitinib

About the Company

Jagsonpal - Legacy of ‘Quality and Trust’ since 1964

100% India Centric Business

PAN India presence; Sub-chronic Presence

Deep Market Penetration

Presence across 4000+ towns and cities through 1200+ distributors, enabling wide accessibility and consistent brand recall.

Quality culture imbibed across Operations

CMOs fully complaint with WHO-GMP and ISO 9001:2015 standards with over 300+ quality checks

Enduring Doctor Confidence

Trusted by >50,000 doctors nationwide – a legacy of prescription confidence built over decades

Therapy powerhouse with deep domain expertise

Spanning branded generics, trade generics & OTC; Ranked #8 in CVM

Power Brand portfolio boosting market share

Top 10 contributing 63% of sales; includes 5 #1 ranked molecules and 14 brands in the top 5

Inorganic growth capabilities, supported by strong balance sheet

Demonstrated strategic acquisition with disciplined integration, driving profitability and margins

Lean Operations: Asset Light Model

Outsourced R&D and Manufacturing; built for growth without capital strain

Backed by promoter conviction, long term vision

Strategic alignment towards long term value creation

Strong Presence in Key Therapies

Gynecology

- 7th as per CMARC RPM in CVM
- Reaching ~90% of the Gynecologists nationwide, engagement with 35,000 out of 39,000 gynaecs.
- Leaders in Progesterone therapeutic segment

Orthopedics

- 2nd as per CMARC RPM in CVM
- Reaching ~80% of the Orthopedists through consistent engagement with 10,000 out of 13,000.
- Strong presence in Osteoporosis and Osteoarthritis segment

Ranked 8th in Corporate CVM (as per CMARC RPM)

Pediatrics

- 17th as per CMARC RPM in CVM
- Maintaining regular connect with 9,700 out of 35,650 Pediatricians, ensuring ~27% coverage.
- Key segments include Gut Health (Probiotic), Cough, Cold & Fever, Anti- itch, Diarrhea and Dysentery

Dermatology

- 30th as per CMARC RPM in CVM
- Operates in Demelanizing, Antifungals
- and Anti-histamines segments
- Regular connect with ~4,500 out of 11,500 Dermatologists in India, ensuring ~40% coverage.

Building A High-impact Asset Light Model

Capital Intensive Activities - Out-Sourced

Ideation

In-house Ideation For Innovative Drug Concepts. 1-2 New Product Launches Every Quarter

Focus On Mid-Sized, Sub Chronic Segment

Aim For Substantial Market Share In Niche Segment

Research & Development

Partner with leading CDMO players for product research and development

Contract Manufacturing

Partner with leading Indian CMO for manufacturing

PAN-India Distribution

1000+ Medical Reps for brand promotion

18 stocking points across the country to ensure last-mile delivery

Strategic Pillars

- Innovation - Niche Molecules, Dominant Market Share
- Large, well trained Work Force of 1000+ Medical Reps
- Lean Operations: Asset Light Model
- Inorganic Growth Powered by Strategic Acquisition

MySakhi Initiative

Where Business Meets Social Impact

Driving Menopause Awareness

Deliver impactful virtual sessions on menopause, supported by social media campaigns and community engagement.

Transforming Hygiene Access

Built modern sanitation complexes across Punjab, Haryana, and Uttarakhand, fostering health and dignity for schoolgirls

Shaping the Future

Expanding outreach with self-testing kits, discounted lab tests, and an online forum to support women’s holistic well-being.

Empowering Women Through MySakhi.in

A dedicated website offering educational resources, health tools, and community support focused on women's health

18 pink toilets built in Haryana, Punjab, Uttarakhand & Delhi NCR Regions

Collaborating with NGOs for hygiene awareness and infrastructure development

Ongoing webinars, spearheaded by specialist doctors focused on Menopause awareness

Key CSR Highlights - FY26

Sanitation





Empowering education with dignity and hygiene

- 9 toilet blocks constructed in FY25-26 across Gurugram, Punjab & Maharashtra (Total: 18)
- Sanitary Pad Vending Machines & Incinerators installed to promote menstrual hygiene
- **9,576** girl students benefited through improved sanitation facilities

Awareness

Creating safe spaces and healthier lives

- **MySakhi Initiative:** Collaborating with doctors to promote awareness on women's health
- Conducted 24 Webinars engaging 1,309 participants
- Topics covered: menopause, nutrition, bone health, mental wellness, and more

Relief

Standing with communities in times of crisis

- Provided financial aid to flood-affected communities in Punjab
- Distributed medicines to affected public
- Timely access to essential healthcare support during emergency conditions
- Supporting communities beyond ongoing CSR initiatives

Thank You

Feel free to reach out to us if you have any questions

JAGSONPAL PHARMACEUTICALS LTD.

Registered Office: Innov8 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi – 110020

cs@jagsonpal.com

www.jagsonpal.com

+91 124 4406710

INVESTOR RELATIONS

Soumya Chhajed

Email: soumya@goindiaadvisors.com

Ph: +91 8619707750